SCHEMBL20111133

SCHEMBL20111133

Cc1cc(-c2c(C)cncc2Cl)cc2c1NC(=O)C2

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRIA1 P42261 7/20 0.70
▸ CACNG8 Q8WXS5 7/20 0.70
▸ CACNG2 Q9Y698 1/20 0.53
▸ AHR P35869 1/20 0.37
▸ CYP1A2 P05177 2/20 0.36
▸ CYP11B1 P15538 2/20 0.36
▸ CYP11B2 P19099 2/20 0.36
▸ PDE3B Q13370 2/20 0.34
▸ PDE3A Q14432 2/20 0.34
▸ BCL6 P41182 1/20 0.34
▸ TDP2 O95551 2/20 0.33
▸ PIK3CG P48736 1/20 0.33
▸ CHEK1 O14757 1/20 0.33
▸ AURKA O14965 1/20 0.33
▸ DAPK3 O43293 1/20 0.33
▸ PRKD3 O94806 1/20 0.33
▸ MAP4K4 O95819 1/20 0.33
▸ ABL1 P00519 1/20 0.33
▸ NTRK1 P04629 1/20 0.33
▸ CSF1R P07333 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18189597 0.95 GRIA1 (0.73) GRIA1CACNG8CACNG2AHRCYP1A2
SCHEMBL18189353 0.93 GRIA1 (0.63) GRIA1CACNG8CACNG2AHRCYP1A2
SCHEMBL18189444 0.88 GRIA1 (0.58) GRIA1CACNG8CACNG2AHRCYP1A2
SCHEMBL18189391 0.84 GRIA1 (0.60) GRIA1CACNG8CACNG2AHRCYP1A2
SCHEMBL20111134 0.83 GRIA1 (0.62) GRIA1CACNG8CACNG2CYP1A2CYP11B1
SCHEMBL18189313 0.83 GRIA1 (1.00) GRIA1CACNG8CACNG2AHRCYP1A2
SCHEMBL18189485 0.83 GRIA1 (1.00) GRIA1CACNG8CACNG2AHRCYP1A2
SCHEMBL20111132 0.82 GRIA1 (0.58) GRIA1CACNG8CACNG2AHRCYP1A2
SCHEMBL18189600 0.82 GRIA1 (0.57) GRIA1CACNG8CACNG2AHRCYP1A2
SCHEMBL18189528 0.80 GRIA1 (0.69) GRIA1CACNG8CACNG2AHRTDP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10604484-B2 Indolone compounds and their use as AMPA receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2020-03-31 — — US disclosed
US-20180118683-A1 INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2018-05-03 — — US disclosed
US-20180118683-A1 INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2018-05-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10604484-B2 Indolone compounds and their use as AMPA receptor modulators GRIN3A, GRIN1, GRIN2B GRIA1 23/4885CACNG8 317/4885CACNG2 370/4885
US-20180118683-A1 INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS GRIN3A, GRIN1, GRIN2B GRIA1 23/4885CACNG8 317/4885CACNG2 370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback